Genfit SA (GNFT) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Genfit SA is making strides in their liver disease programs, with Ipsen set to present new data on elafibranor at The Liver Meeting 2024 and positive commercial progress in the U.S. and Europe. The company is also advancing its Acute-on-Chronic Liver Failure (ACLF) program, with multiple clinical trials planned for 2025 and recent protocol improvements to enhance trial recruitment. These developments highlight Genfit’s commitment to expanding its presence in the liver health sector and improving patient outcomes.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
